GovBidPulseFormDPulseAccessPulseCitePulseLocalSchemaPulseIntelligence feedsSupport

FormDPulse / report

EVIA Life Sciences Inc. raised $700,002 (Tokyo, M0)

LIVE PUBLIC DATA Source: SEC EDGAR Form D filings (U.S. Securities and Exchange Commission) · Last refreshed: Wed, 04 Nov 2026 01:28:40 GMT

EVIA Life Sciences Inc. plus every comparable record, with all columns and source links, as one CSV.

Not investment advice and not an offer or solicitation to buy or sell any security.

63 / 100 vendor spend propensity

Estimated post-raise budget for CPA / Tax / Audit services: $14,000 (heuristic)

  • Operating company: new capital typically funds hiring, facilities and vendors.
  • Raised $700,002 so far: a smaller raise.
  • Healthcare & Life Sciences companies are a strong fit for CPA / Tax / Audit services.
  • New filing (not an amendment): the raise is fresh.
  • Filed 2 days ago.
FieldValue
IndustryBiotechnology (Healthcare & Life Sciences)
Operating companyYes
Exemption506(b)
Amount sold$700,002
Total offering$5,498,154
Investors so far1
First sale2026-10-23
Filed2026-11-02
EntityCorporation

Executives and related persons (from the filing)

  • Kosuke Takishima: Executive Officer
  • Joshua Raphael Schwab: Director
  • Michael Kim: Director
  • Takahiro Ochiya: Director

View the filing on SEC EDGAR

Markdown version

EVIA Life Sciences Inc. vs. top 3 peers

OrganizationLocationCapital raisedRecord date
EVIA Life Sciences Inc.Tokyo$700,0022026-11-02
Tru Singular Health, Inc.Natick$1,000,0002026-10-30
Accufy Diagnostics, Inc.Rockville$2,000,0002026-10-28
PCFM Investments, LLCMurray$2,028,6002026-10-28

Related records

Newly funded Healthcare & Life Sciences companies (SEC Form D)

Get new raises like this every morning

FormDPulse emails you newly funded companies that match your ideal customer profile.

See plans

Often used together

Or get the Advisor Prospecting Bundle for $14.99 one-time: Full CSV unlock of newly funded companies plus a grant readiness pack.